f77dku12 | Knowledge4COVID-19

Property	Value
?:abstract	In this viewpoint, Robert Califf, former commissioner of the U.S. Food and Drug Administration, and colleagues reflect on how to approach questions about which patient treatments and strategies work, particularly in light of the tremendous pressure on the government and biomedical research enterprise to quickly develop safe, effective therapies during the SARS-CoV-2 pandemic.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/f77dku12_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Califf%2C_Robert_M%3B_Curtis%2C_Lesley_H%3B_Harrington%2C_Robert_A%3B_Hernandez%2C_Adrian_F%3B_Peterson%2C_Eric_D>
?:doi	<https://research.tib.eu/covid-19/entity/10.1172/jci146391>
?:doi	10.1172/jci146391
?:journal	The_Journal_of_clinical_investigation
?:license	unk
?:pmid	<https://research.tib.eu/covid-19/entity/33270604>
?:pmid	33270604
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	Medline
?:title	Generating evidence for therapeutic effects: the need for well-conducted randomized trials.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-03

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/f77dku12>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/f77dku12>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all